Lv6
1920 积分 2024-09-29 加入
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
26天前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
P265: Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
2个月前
已完结
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
2个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
3个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
3个月前
已关闭
Ⅳ期乳腺癌局部治疗研究进展与解析
3个月前
已关闭
Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
3个月前
已关闭
Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
3个月前
已关闭
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
4个月前
已完结
皖公网安备34019202002308
